Under the Paperwork Reduction Act of 1995, no persons are required

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10806633			
Filing Date		2004-03-22			
First Named Inventor	Dimp	psey et al.			
Art Unit		2188			
Examiner Name	Moore, Patrick M.				
Attorney Docket Number		AUS920040062US1			

				Audiney	,	Ket Hullibei	Auto	20040002	001			
					U.S.I	PATENTS				Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Dat	to	Name of Patentee or Applican of cited Document		Applicant	Pages,Columns,Lines w Relevant Passages or F Figures Appear			
	1	6973417	B1	2005-12-0	06	Maxwell et al.						
	2	6721875	B1	2004-04-1	13	McCormick et	tal.					
If you wish	to a	dd additional U.S. Pate	nt citatio	n informat	tion pl	ease click the	Add butts	on.		Add		
_			U.S.P	ATENT A	PPLK	CATION PUB	LICATIO	NS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	on	Name of Pat of cited Docu		Applicant	Releva		ines where es or Relev	
lf you wish	n to a	dd additional U.S. Publ	shed Ap			n information p		ck the Ad	d buttor	Add		
	_			POREIGI	TAI	ENI DOCCII	LINIS		_		umns.Lines	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Code <sup>2</sup>		Kind Code4	Publication Date		f Patente nt of cited ent	e or	where Rele	vant or Relevant	T.
	1											Е
If you wish	n to a	dd additional Foreign P							button	Add		_
			NON	4-PATENT	LITE	RATURE DO	CUMENT	S		remove		

	Application Number		10806633		
NEODWATION DIGGI COURT	Filing Date		2004-03-22		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Dimp		npsey et al.		
Not for submission under 37 CFR 1.99)	Art Unit		2188		
· · · · · · · · · · · · · · · · · · ·	Examiner Name Moor		oore, Patrick M.		
	Attorney Docket Numb	er	AUS920040062US1		

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5
	1		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

## Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Knd Codes of USPTO Patent Documents at year USPTO, GOV or MPEP 801.8.2 Either office that issued the document, by the bo-batter code (WIPO Standard ST3.3) are fragatese patent concerned, the shadoon of the year of the Emperor most procedule the serial number of the submotive consumest to countered. If which document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 3 Applicant is to place a check mark their if English language the instaltation is attacked.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number Filing Date		10806633
			2004-03-22
First Named Inventor Dimp		Dimp	osey et al.
	Art Unit		2188
Examiner Name Moore		Moor	e, Patrick M.
	Attorney Docket Number		AUS920040062US1

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, to fixer of information contained in the information disclosure statement was known to 2 any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Gerald H. Glanzman/	Date (YYYY-MM-DD)	2006-08-29					
Name/Print	Gerald H. Glanzman	Registration Number	25035					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenant Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, V.3.231.1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issuand patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.